Cell line · CVCL_1379
Papers70
43 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 70
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Vitronectin Enrichment in Prostate Cancer Liver Metastases Promotes Adhesion and Survival. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Spatiotemporal Atlas of the Androgen Receptor Proximal Interactome. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi-omics dissection of FOXA1 reveals cancer-type-specific transcriptional networks and functional risk variants. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SPEN Inactivation Drives Resistance to Androgen Receptor Pathway Inhibitors in Metastatic Prostate Cancer. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ERG Orchestrates a Dedifferentiation-Senescence-Inflammation Triad in Prostate Cancer. | Mol Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3-Directed and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PVT1 lincRNA signals an androgen-dependent transcriptional activation program of oncogenes in prostate cancer cells. | Int J Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| GNL3 Orchestrates AR Transcriptional Programs to Drive Castration-Resistant Prostate Cancer and Immune Evasion. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Increasing Cancer Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient Survival. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Androgen receptor contributes to radioresistance through DNA repair and autophagy in AR-positive prostate cancer cells. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. | Sci Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer. | Int J Nanomedicine | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| A Compound That Inhibits Glycolysis in Prostate Cancer Controls Growth of Advanced Prostate Cancer. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells. | Cancer Cell | 2024 | Its Methods give the RRID and name the line | PubMed | |
| cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression. | Mol Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| FAM120A couples SREBP-dependent transcription and splicing of lipogenesis enzymes downstream of mTORC1. | Mol Cell | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1379/papers